Clinical trial
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)
NCT05178862 is registered in ClinicalTrials.gov with Scynexis, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)
- Lead sponsor
- Scynexis, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 3, 2022
- Completion date
- December 16, 2025
- Enrollment
- 68 (actual)
- Sites
- 101
Conditions
As the registry lists them; a condition with its own page is linked.